These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35580987)

  • 1. DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITF.
    Gutierrez-Prat N; Zuberer HL; Mangano L; Karimaddini Z; Wolf L; Tyanova S; Wellinger LC; Marbach D; Griesser V; Pettazzoni P; Bischoff JR; Rohle D; Palladino C; Vivanco I
    Life Sci Alliance; 2022 Sep; 5(9):. PubMed ID: 35580987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells.
    Pathria G; Garg B; Borgdorff V; Garg K; Wagner C; Superti-Furga G; Wagner SN
    Cell Death Dis; 2016 Mar; 7(3):e2135. PubMed ID: 26962685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.
    Najem A; Krayem M; Salès F; Hussein N; Badran B; Robert C; Awada A; Journe F; Ghanem GE
    Eur J Cancer; 2017 Sep; 83():154-165. PubMed ID: 28738256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy.
    Smith MP; Brunton H; Rowling EJ; Ferguson J; Arozarena I; Miskolczi Z; Lee JL; Girotti MR; Marais R; Levesque MP; Dummer R; Frederick DT; Flaherty KT; Cooper ZA; Wargo JA; Wellbrock C
    Cancer Cell; 2016 Mar; 29(3):270-284. PubMed ID: 26977879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
    Konieczkowski DJ; Johannessen CM; Abudayyeh O; Kim JW; Cooper ZA; Piris A; Frederick DT; Barzily-Rokni M; Straussman R; Haq R; Fisher DE; Mesirov JP; Hahn WC; Flaherty KT; Wargo JA; Tamayo P; Garraway LA
    Cancer Discov; 2014 Jul; 4(7):816-27. PubMed ID: 24771846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma.
    Fedorenko IV; Fang B; Munko AC; Gibney GT; Koomen JM; Smalley KS
    Proteomics; 2015 Jan; 15(2-3):327-39. PubMed ID: 25339196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers.
    Ito T; Young MJ; Li R; Jain S; Wernitznig A; Krill-Burger JM; Lemke CT; Monducci D; Rodriguez DJ; Chang L; Dutta S; Pal D; Paolella BR; Rothberg MV; Root DE; Johannessen CM; Parida L; Getz G; Vazquez F; Doench JG; Zamanighomi M; Sellers WR
    Nat Genet; 2021 Dec; 53(12):1664-1672. PubMed ID: 34857952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma.
    Wong DJ; Robert L; Atefi MS; Lassen A; Avarappatt G; Cerniglia M; Avramis E; Tsoi J; Foulad D; Graeber TG; Comin-Anduix B; Samatar A; Lo RS; Ribas A
    Mol Cancer; 2014 Aug; 13():194. PubMed ID: 25142146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma.
    Gupta A; Towers C; Willenbrock F; Brant R; Hodgson DR; Sharpe A; Smith P; Cutts A; Schuh A; Asher R; Myers K; Love S; Collins L; Wise A; Middleton MR; Macaulay VM
    Br J Cancer; 2020 Feb; 122(4):506-516. PubMed ID: 31839677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway.
    Gupta R; Bugide S; Wang B; Green MR; Johnson DB; Wajapeyee N
    Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4583-4591. PubMed ID: 30782837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of CEACAM1 Protein Expression by the Transcription Factor ETS-1 in BRAF-Mutant Human Metastatic Melanoma Cells.
    Kfir-Elirachman K; Ortenberg R; Vizel B; Besser MJ; Barshack I; Schachter J; Nemlich Y; Markel G
    Neoplasia; 2018 Apr; 20(4):401-409. PubMed ID: 29558679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of
    Aloia A; Müllhaupt D; Chabbert CD; Eberhart T; Flückiger-Mangual S; Vukolic A; Eichhoff O; Irmisch A; Alexander LT; Scibona E; Frederick DT; Miao B; Tian T; Cheng C; Kwong LN; Wei Z; Sullivan RJ; Boland GM; Herlyn M; Flaherty KT; Zamboni N; Dummer R; Zhang G; Levesque MP; Krek W; Kovacs WJ
    Clin Cancer Res; 2019 Nov; 25(22):6852-6867. PubMed ID: 31375515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways.
    Adam C; Fusi L; Weiss N; Goller SG; Meder K; Frings VG; Kneitz H; Goebeler M; Houben R; Schrama D; Schmidt M
    J Invest Dermatol; 2020 Dec; 140(12):2455-2465.e10. PubMed ID: 32376279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. E3 ubiquitin ligase PARK2, an inhibitor of melanoma cell growth, is repressed by the oncogenic ERK1/2-ELK1 transcriptional axis.
    Montagnani V; Maresca L; Apollo A; Pepe S; Carr RM; Fernandez-Zapico ME; Stecca B
    J Biol Chem; 2020 Nov; 295(47):16058-16071. PubMed ID: 32938713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.
    Niessner H; Sinnberg T; Kosnopfel C; Smalley KSM; Beck D; Praetorius C; Mai M; Beissert S; Kulms D; Schaller M; Garbe C; Flaherty KT; Westphal D; Wanke I; Meier F
    Clin Cancer Res; 2017 Oct; 23(20):6203-6214. PubMed ID: 28724666
    [No Abstract]   [Full Text] [Related]  

  • 16. The MITF/mir-579-3p regulatory axis dictates BRAF-mutated melanoma cell fate in response to MAPK inhibitors.
    Liguoro D; Frigerio R; Ortolano A; Sacconi A; Acunzo M; Romano G; Nigita G; Bellei B; Madonna G; Capone M; Ascierto PA; Mancini R; Ciliberto G; Fattore L
    Cell Death Dis; 2024 Mar; 15(3):208. PubMed ID: 38472212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
    Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEK Inhibition Reverses Aberrant Signaling in Melanoma Cells through Reorganization of NRas and BRAF in Self Nanoclusters.
    Yakovian O; Sajman J; Arafeh R; Neve-Oz Y; Alon M; Samuels Y; Sherman E
    Cancer Res; 2021 Mar; 81(5):1279-1292. PubMed ID: 33355187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vemurafenib resistance reprograms melanoma cells towards glutamine dependence.
    Hernandez-Davies JE; Tran TQ; Reid MA; Rosales KR; Lowman XH; Pan M; Moriceau G; Yang Y; Wu J; Lo RS; Kong M
    J Transl Med; 2015 Jul; 13():210. PubMed ID: 26139106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.
    Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG
    Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.